Friday 6 November 2026 Export SINT’s income statement to Excel — free account

SINTX TECHNOLOGIES, INC.

SINTX TECHNOLOGIES, INC.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, down 64.7% from fiscal 2024.

Revenue: +952.9%
EPS: +93.1%
Free cash flow: +47.4%
Total debt: −6.78%

Quarter to September 2026, against a year earlier

Insider buying

1.56 0.06 −3.70%

Follow SINT

Alert me

Market cap: $11.5M
P/E: 0.0×
Fwd P/E: −0.9×
Dividend yield: —
F-score: 2/9
Altman Z: −45.42
Beneish M: −3.03
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 0.33

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	2	—	3	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 14.34%

Capital & Financial Ratios $m

Size

Market Cap 11.53

Revenue ttm 3.31

Net income ttm (9.34)

Free cash flow ttm (8.97)

Net debt Q (1.95)

Valuation

P/E 0.00

Forward P/E (0.93)

Price / sales 3.14

Forward P/S Powerpack

Price / FCF 0.00

Price / book 3.07

Financial health

Current ratio Q 1.84

Debt / equity Q 0.02

Interest coverage Q (817.50)

Growth

Revenue growth Q +952.88%

Operating income growth Q +51.27%

EPS, this year +70.29%

EPS, next year A +40.98%

Revenue, next year A +217.19%

EPS, past 5 yrs —

EPS, next 5 yrs A +54.77%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 32.42%

10-year low 10-year high

P/B against its own 10 years 69.15%

10-year low 10-year high

EV/Sales against its own 10 years 15.38%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3	4	4	2
Receivables	1	0	0	0
Inventory	1	1	1	3
Other	0	0	—	—
	6	5	6	6

	2023	2024	2025	Q'26
Payables	1	0	0	1
ST’ Debt	0	0	0	0
Other	0	0	3	0
	3	2	4	3

Compound Annual Growth %

	10y	5y	3y
Sales	(26.71%)	11.38%	(13.28%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(14.62%)	(35.28%)	(19.92%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.81 Actual −0.75

−3.93 −2.91 −1.89 −0.86 0.16

Q2 FY25 Miss −0.12

Q3 FY25 Miss −2.91

Q1 FY26 Miss −0.04

Q2 FY26 Beat +0.06

Q3 FY26 — Nov 5

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q2 FY25	−0.79	−0.91	Miss by 0.12
Q3 FY25	−0.55	−3.46	Miss by 2.91
Q1 FY26	−0.66	−0.70	Miss by 0.04
Q2 FY26	−0.81	−0.75	Beat by 0.06
Q3 FY26	−0.31	—	Reports 5 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.70)	(0.75)	(0.24)	—	—
’25	(1.29)	(0.91)	(3.46)	(0.58)	(6.16)
’24	(5.14)	(3.61)	(6.95)	(1.25)	(15.19)
’23	(22.91)	(110.67)	(161.21)	(100.49)	(624.47)
’22	(2.40k)	(2.00k)	(2.17k)	(1.11k)	(12.16k)
’21	(2.13k)	(1.80k)	(1.87k)	(1.64k)	(7.43k)
’20	(30.60k)	(7.00k)	(2.20k)	(2.18k)	(21.60k)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	2	—	—
’25	0	0	0	0	1
’24	1	1	1	1	3
’23	1	1	1	1	3
’22	0	0	0	1	2
’21	0	0	0	0	1
’20	0	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(3)	(1)	—	—
’25	(1)	(2)	(3)	(2)	(9)
’24	(3)	(2)	(3)	(1)	(9)
’23	(5)	(3)	(3)	(3)	(14)
’22	(3)	(3)	(2)	(2)	(10)
’21	(3)	(2)	(2)	(2)	(10)
’20	(3)	(2)	(2)	(2)	(9)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(3)	(1)	—	—
’25	(1)	(2)	(3)	(2)	(8)
’24	(3)	(3)	(3)	(1)	(9)
’23	(5)	(3)	(3)	(3)	(15)
’22	(3)	(3)	(3)	(2)	(12)
’21	(3)	(3)	(5)	(3)	(14)
’20	(3)	(2)	(2)	(2)	(9)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Sep ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	15	—	0	1	1	1	2	3	3	1	3		(26.0%)	3	6	31	+213.3%
	Gross margin, %	75.19	0.00	41.05	20.03	20.03	25.91	83.02	70.16	71.91	45.28	59.54		(29.9) pt	Powerpack SINTX TECHNOLOGIES, INC.’s next three years, line by line Analysts expect revenue to grow 213.3% a year to 2028 — faster than the −26.0% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(15)	(6)	(10)	(5)	(7)	(9)	(12)	(8)	(11)	(10)	(9)		(3.9%)
	EBT margin, %	(96.96)	0.00	(10,198.95)	(696.23)	(1,183.33)	(1,536.14)	(771.24)	(314.39)	(381.85)	(1,018.07)	(281.91)		(921.1) pt
	Net income	(15)	(6)	(10)	(5)	(7)	(9)	(12)	(8)	(11)	(10)	(9)		(3.9%)
Per share, $
Per share, $	Revenue	5,917,835.91	0.00	0.00	8,856.11	724.10	505.00	1,035.11	140.48	3.89	0.37	0.50		(84.2%)
	Earnings	(8,177,958.00)	(1,879,013.22)	(1,237,237.00)	(96,401.77)	(20,228.50)	(7,105.40)	(10,933.99)	(444.00)	(14.87)	(6.16)	(2.27)		(79.1%)
	Cash flow	(2,786,738.70)	(942,636.16)	0.00	(82,712.72)	(11,107.75)	(8,439.17)	(6,805.48)	(754.81)	(11.66)	(3.09)	(1.35)		(78.2%)
	Capex	(239,807.22)	(1,208.51)	0.00	(1,889.47)	(438.85)	(3,000.00)	(931.00)	(26.79)	(0.90)	0.06	0.00		n/m
	Free cash flow	(3,026,545.92)	(943,844.67)	0.00	(84,602.19)	(11,546.60)	(11,439.17)	(7,736.48)	(781.60)	(12.56)	(3.03)	(1.35)		(78.5%)
	Book value	4,366,667.96	1,096,116.66	0.00	66,864.27	31,455.72	14,329.17	3,782.37	469.09	5.25	1.06	0.51		(81.6%)
	Shares, m	0	0	0	0	0	0	0	0	1	3	5		+368.0%
Valuation, ×
Valuation, ×	P/E	0.00	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	472,387.34	—	0.00	4.33	42.29	25.42	1.85	0.65	1.64	10.52	3.14		52,497.1
	P/B	640,193.11	—	0.00	0.57	0.97	0.90	0.50	0.19	1.21	3.66	3.07		71,133.5
	EV/Sales	472,387.35	—	(0.41)	1.76	0.28	5.84	(1.82)	(0.60)	0.41	6.47	2.55		52,488.8
	EV/FCF	(923,663.76)	—	0.59	(0.19)	(0.02)	(0.26)	0.24	0.11	(0.13)	(0.78)	(0.92)		(102,629.4)
Cash, $m
Cash, $m	Operating cash flow	(7)	(5)	(9)	(6)	(9)	(10)	(10)	(14)	(9)	(9)	(9)		+2.0%
	Capex	(1)	0	0	0	0	(4)	(1)	(1)	(1)	0	0		n/m
	Free cash flow	(8)	(5)	(9)	(7)	(9)	(14)	(12)	(15)	(9)	(8)	(9)		+0.9%
Balance, $m
Balance, $m	Working capital	2	(5)	5	2	25	12	(1)	3	3	2	3		(0.5%)
	Net debt	0	0	(5)	(2)	(25)	(12)	(6)	(3)	(4)	(4)	(2)		n/m
	Shareholders’ equity	11	5	8	5	26	17	6	9	4	3	3		(13.9%)
Returns, %
Returns, %	ROA	(67.74)	(45.62)	(172.44)	(72.60)	(83.82)	(35.61)	(87.68)	(53.21)	(88.98)	(180.59)	0.00		(112.9) pt
	ROIC	(63.62)	(84.93)	(262.66)	(120.05)	(626.03)	(124.55)	0.00	(152.41)	(2,676.64)	0.00	(436.11)		+63.6 pt
	ROE	(165.24)	(111.88)	(325.87)	(110.29)	(107.04)	(43.30)	(144.02)	(114.47)	(174.07)	(500.75)	0.00		(335.5) pt
People
People	Employees	35	33	19	28	32	36	41	43	20	32	—		(1.0%)
	Revenue/emp, $m	0.44	0.00	0.01	0.02	0.02	0.02	0.04	0.06	0.14	0.03	—		(25.2%)

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RBOT Vicarious Surgical Inc.	$14.3M	— (loss-making)	—	—	n/m	+47.33% (above 0%: growing)	0.00%	0.00%	Compare
HSCS HeartSciences Inc.	$13.3M	— (loss-making)	— (loss-making)	−46.15% (below 0%: shrinking)	n/m	+18.18% (above 0%: growing)	61.90%	(139,957.14%)	Compare
PETV PetVivo Holdings, Inc.	$12.9M	— (loss-making)	— (loss-making)	+13.48% (above 0%: growing)	n/m	+40.13% (above 0%: growing)	66.14%	(476.54%)	Compare
ITOC iTonic Holdings Ltd.	$12.4M	—	—	—	—	—	—	—	Compare
PAVM PAVmed Inc.	$12.4M	— (loss-making)	— (loss-making)	+450.00% (above 0%: growing)	n/m	−125.63% (below 0%: shrinking)	(269.70%)	(21,278.79%)	Compare
MODD Modular Medical, Inc.	$12.2M	— (loss-making)	—	—	n/m	−5.61% (below 0%: shrinking)	0.00%	0.00%	Compare
IRIX IRIDEX Corporation	$11.9M	— (loss-making)	— (loss-making)	−7.41% (below 0%: shrinking)	n/m	+130.24% (above 0%: growing)	34.19%	(8.19%)	Compare
SINT SINTX TECHNOLOGIES, INC.	$11.5M	— (loss-making)	— (loss-making)	+952.88% (above 0%: growing)	n/m	+47.37% (above 0%: growing)	62.19%	(74.66%)
BTCY Biotricity Inc.	$10.9M	— (loss-making)	— (loss-making)	+10.40% (above 0%: growing)	n/m	+235.83% (above 0%: growing)	82.55%	3.70%	Compare
Median of peers	$12.4M	—	—	+10.40%	—	+40.13%	34.19%	(8.19%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 30 October 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	1.05m	1.05m	(99.80)
2024	440.65k	411.27k	(99.82)
2023	537.31k	461.68k	(96.06)

Ownership

Directors and executive officers, together 8.10%

Medtech Ceramics, LP 9.90%

Laurence W Lytton 9.90%

Bleichroeder LP 9.90%

D. Kent Lance, Jr. 8.30%

Stonepine Capital Management, LLC 8.30%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

SINTX TECHNOLOGIES, INC. (SINT) Latest News

6 Nov

Impact 3 · 12:27 AM · GuruFocus.com

SINTX Technologies Inc (SINT) (Q3 2026) Earnings Call Highlights: Record Revenue Surge and ...

5 Nov

Impact 3 · 4:02 PM · GlobeNewswire

SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization

22 Oct

Impact 3 · 9:00 AM · GlobeNewswire

SINTX Technologies Announces Third Quarter 2026 Earnings Release Date and Webcast

8 Oct

Impact 3 · 11:00 AM · Zacks

What Makes SINTX TECHNOLOGIES (SINT) a New Buy Stock

1 Oct

Impact 4 · 9:00 AM · GlobeNewswire

SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance

12 Aug

Impact 4 · 1:02 AM

SINTX Technologies Inc (SINT) (Q2 2026) Earnings Call Highlights: Revenue Surges 199% as ...

Impact 3 · 8:30 AM · Moby transcript

Sintx Technologies, Inc. Q2 2026 Earnings Call Summary

11 Aug

Impact 4 · 4:06 PM

SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives

22 Jun

Impact 3 · 9:00 AM · GlobeNewswire

SINTX Technologies Announces Receipt of More Than $3.2 Million in Contract Manufacturing Purchase Orders

3 Jun

Impact 3 · 9:00 AM · GlobeNewswire

SINTX Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

23 Mar

Impact 4 · 9:15 AM · GlobeNewswire

SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

19 Mar

Impact 4 · 7:30 AM · GlobeNewswire

SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

18 Feb

Impact 4 · 8:30 AM · GlobeNewswire

SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

1 Dec

Impact 4 · 8:30 AM · GlobeNewswire

SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants

13 Nov

Impact 4 · 8:00 AM · GlobeNewswire

SINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational Efficiencies

3 Nov

Impact 4 · 8:00 AM

SINTX Technologies Announces Launch of OsseoSculpt™ an Advanced Biologic for Use with SINAPTIC® Foot & Ankle Osteotomy Wedge System

20 Oct

Impact 4 · 7:00 AM · GlobeNewswireMedical Device NetworkMedTech DiveMedical Device NetworkMedical Device NetworkMedical Device NetworkZacksMT Newswires

SINTX Technologies Receives FDA Clearance for SINAPTIC® Foot & Ankle Implant System

16 Oct

Impact 4 · 12:00 PM · Zacks

What Makes SINTX TECHNOLOGIES, INC. (SINT) a Strong Momentum Stock: Buy Now?

Impact 4 · 7:00 AM · GlobeNewswireMT NewswiresSimply Wall St.TipRanksTipRanksMT NewswiresGuruFocus.comSimply Wall St.

UPDATE: SINTX Strengthens Infection-Prevention Portfolio with Newly Allowed U.S. Patent Covering $30 Billion Antipathogenic Addressable Market

14 Oct

Impact 4 · 7:00 AM · GlobeNewswire

SINTX Technologies Strengthens IP Portfolio with New U.S. Patent Notice of Allowance Covering Antipathogenic Fabrics

18 Sep

Impact 4 · 7:19 AM

Several Insiders Invested In Sintx Technologies Flagging Positive News

8 Sep

Impact 4 · 7:00 AM

SINTX Technologies Receives USPTO Notice of Allowance for Silicon Nitride Antipathogenic Platform Patent

Impact 3 · 7:54 AM

SINTX Technologies Announces Successful Exercise of Warrants for $3.8 Million Gross Proceeds

5 Sep

Impact 3 · 1:46 PM · MT Newswires

Top Midday Gainers

3 Sep

Impact 4 · 7:00 AM · GlobeNewswire

SINTX Technologies Publishes Landmark Study Demonstrating Broad-Spectrum Antiviral Activity of Silicon Nitride

Impact 3 · 10:30 AM · Associated Press Finance

BC-Most Active Stocks

25 Aug

Impact 3 · 6:00 AM · PR Newswire

3D Printing Ceramics Market worth $0.97 billion by 2030 - Exclusive Report by MarketsandMarkets™

15 Aug

Impact 4 · 7:00 AM · GlobeNewswire

SINTX Technologies Issues Business Update Following Strategic Realignment, Leadership Expansion, and SiNAPTIC Acquisition

4 Aug

Impact 4 · 7:00 AM · GlobeNewswire

SINTX Technologies Expands Silicon Nitride Platform into Hybrid CFR-PEKK Trauma Plates

22 Jul

Impact 4 · 7:00 AM · GlobeNewswire

SINTX Technologies Submits FDA 510(k) for Silicon Nitride Foot & Ankle Medical Devices

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

SINTX TECHNOLOGIES, INC. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 30 October 2026

Chief executive’s pay

Ownership

SINTX TECHNOLOGIES, INC. (SINT) Latest News

6 Nov

5 Nov

22 Oct

8 Oct

1 Oct

12 Aug

11 Aug

22 Jun

3 Jun

23 Mar

19 Mar

18 Feb

1 Dec

13 Nov

3 Nov

20 Oct

16 Oct

14 Oct

18 Sep

8 Sep

5 Sep

3 Sep

25 Aug

15 Aug

4 Aug

22 Jul

Stockrow Weekly